$CHRS
Coherus BioSciences Inc

2022 Q3 Form 10-Q Financial Statement

#000155837022012251 Filed on August 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $45.40M $60.20M $60.12M
YoY Change -44.97% -31.28% -27.6%
Cost Of Revenue $35.23M $11.28M $9.370M
YoY Change 65.57% -32.46% 24.75%
Gross Profit $10.17M $48.92M $50.75M
YoY Change -83.4% -31.0% -32.81%
Gross Profit Margin 22.39% 81.27% 84.41%
Selling, General & Admin $44.83M $51.28M $48.75M
YoY Change 12.29% 27.09% 23.77%
% of Gross Profit 440.99% 104.81% 96.07%
Research & Development $45.81M $41.61M $82.92M
YoY Change -15.3% -24.02% -59.25%
% of Gross Profit 450.6% 85.05% 163.4%
Depreciation & Amortization $995.0K $887.0K $767.0K
YoY Change 11.55% -4.21% -4.13%
% of Gross Profit 9.79% 1.81% 1.51%
Operating Expenses $90.64M $92.89M $131.7M
YoY Change -3.59% -2.34% -45.79%
Operating Profit -$80.45M -$44.01M -$80.93M
YoY Change 145.37% 82.14% -51.65%
Interest Expense $7.540M $6.580M $8.969M
YoY Change 30.65% 14.49% 58.8%
% of Operating Profit
Other Income/Expense, Net $1.339M $443.0K $32.00K
YoY Change 4363.33% 3927.27% -47.54%
Pretax Income -$86.65M -$50.15M -$96.08M
YoY Change 124.9% 67.73% -44.44%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$86.65M -$50.15M -$96.08M
YoY Change 124.9% 67.73% -44.44%
Net Earnings / Revenue -190.86% -83.31% -159.83%
Basic Earnings Per Share -$1.11 -$0.65 -$1.24
Diluted Earnings Per Share -$1.11 -$0.65 -$1.24
COMMON SHARES
Basic Shares Outstanding 77.72M 77.55M 77.25M
Diluted Shares Outstanding 77.75M 77.55M 77.25M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $286.8M $275.5M $325.7M
YoY Change -38.81% -39.38% -18.48%
Cash & Equivalents $286.8M $275.5M $325.7M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $42.57M $23.85M $32.78M
YoY Change 40.0% -1.05% 27.54%
Inventory $27.72M $31.74M $36.95M
Prepaid Expenses
Receivables $91.19M $115.7M $117.0M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $448.3M $446.8M $512.4M
YoY Change -33.4% -32.31% -16.98%
LONG-TERM ASSETS
Property, Plant & Equipment $9.571M $9.553M $7.998M
YoY Change 12.53% -47.02% -58.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $9.627M $10.15M $9.956M
YoY Change -6.19% -2.41% -6.95%
Total Long-Term Assets $102.6M $99.22M $80.94M
YoY Change 49.42% 24.76% 6.45%
TOTAL ASSETS
Total Short-Term Assets $448.3M $446.8M $512.4M
Total Long-Term Assets $102.6M $99.22M $80.94M
Total Assets $550.9M $546.0M $593.4M
YoY Change -25.73% -26.17% -14.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.917M $17.49M $21.09M
YoY Change -78.3% 20.03% 36.24%
Accrued Expenses $85.99M $41.79M $45.89M
YoY Change 87.64% -23.87% 2.35%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $171.3M $140.8M $153.7M
YoY Change -46.52% -50.97% -40.32%
LONG-TERM LIABILITIES
Long-Term Debt $470.5M $421.0M $420.5M
YoY Change 66.9% 46.64% 40.67%
Other Long-Term Liabilities $102.0K $102.0K $102.0K
YoY Change -86.4% -86.42% -86.4%
Total Long-Term Liabilities $102.0K $102.0K $102.0K
YoY Change -86.4% -86.42% -86.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $171.3M $140.8M $153.7M
Total Long-Term Liabilities $102.0K $102.0K $102.0K
Total Liabilities $648.0M $568.6M $580.8M
YoY Change 6.07% -2.52% 2.69%
SHAREHOLDERS EQUITY
Retained Earnings -$1.283B -$1.196B -$1.146B
YoY Change 27.75% 23.87% 22.47%
Common Stock $7.000K $7.000K $7.000K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$97.13M -$22.63M $12.56M
YoY Change
Total Liabilities & Shareholders Equity $550.9M $546.0M $593.4M
YoY Change -25.73% -26.17% -14.41%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$86.65M -$50.15M -$96.08M
YoY Change 124.9% 67.73% -44.44%
Depreciation, Depletion And Amortization $995.0K $887.0K $767.0K
YoY Change 11.55% -4.21% -4.13%
Cash From Operating Activities -$37.09M -$50.04M -$54.05M
YoY Change -370.51% 22541.18% -4053.55%
INVESTING ACTIVITIES
Capital Expenditures -$457.0K -$880.0K $615.0K
YoY Change 75.1% 91.3% 324.14%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 -$35.00M
YoY Change -100.0% -100.0% -87.73%
Cash From Investing Activities -$457.0K -$880.0K -$35.62M
YoY Change -102.86% -103.73% -87.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 48.87M 721.0K -1.855M
YoY Change 4338.42% -98.46% -176.06%
NET CHANGE
Cash From Operating Activities -37.09M -50.04M -54.05M
Cash From Investing Activities -457.0K -880.0K -35.62M
Cash From Financing Activities 48.87M 721.0K -1.855M
Net Change In Cash 11.32M -50.20M -91.52M
YoY Change -63.25% -171.42% -67.51%
FREE CASH FLOW
Cash From Operating Activities -$37.09M -$50.04M -$54.05M
Capital Expenditures -$457.0K -$880.0K $615.0K
Free Cash Flow -$36.63M -$49.16M -$54.66M
YoY Change -362.18% -20667.78% -4573.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.89
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.73
dei Document Type
DocumentType
10-Q
CY2021Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77554717
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75559697
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77405040
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74203858
dei Entity Central Index Key
EntityCentralIndexKey
0001512762
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
CY2022Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
dei Entity Small Business
EntitySmallBusiness
false
CY2021Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2022Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
76930096
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77702749
dei Entity File Number
EntityFileNumber
001-36721
dei Entity Registrant Name
EntityRegistrantName
Coherus BioSciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3615821
dei Entity Address Address Line1
EntityAddressAddressLine1
333 Twin Dolphin Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94065
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
649-3530
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
CHRS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
77724589
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
275484000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
417195000
CY2022Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
115711000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
123022000
CY2022Q2 us-gaap Inventory Net
InventoryNet
31744000
CY2021Q4 us-gaap Inventory Net
InventoryNet
37642000
CY2022Q2 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
7176000
CY2021Q4 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
13666000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16669000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10798000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
446784000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
602323000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9553000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7813000
CY2022Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
75954000
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
55610000
CY2022Q2 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
3563000
CY2021Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
3563000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10149000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10025000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
22014000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
41793000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77702749
CY2022Q2 us-gaap Assets
Assets
546003000
CY2021Q4 us-gaap Assets
Assets
679334000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
17486000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16159000
CY2022Q2 chrs Accrued Rebates Fees And Reserve Current
AccruedRebatesFeesAndReserveCurrent
64547000
CY2021Q4 chrs Accrued Rebates Fees And Reserve Current
AccruedRebatesFeesAndReserveCurrent
79027000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
16928000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
48127000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
140754000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
165327000
CY2022Q2 chrs Term Loans Payable Noncurrent
TermLoansPayableNoncurrent
196037000
CY2021Q4 chrs Term Loans Payable Noncurrent
TermLoansPayableNoncurrent
75513000
CY2022Q2 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
224928000
CY2021Q4 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
332767000
CY2022Q2 chrs Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
6811000
CY2021Q4 chrs Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
7251000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
102000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
750000
CY2022Q2 us-gaap Liabilities
Liabilities
568632000
CY2021Q4 us-gaap Liabilities
Liabilities
581608000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76930096
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
7000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1173722000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1147843000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-270000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-270000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1196088000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1049854000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-22629000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
97726000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
546003000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
679334000
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
60151000
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
87643000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
120266000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
170677000
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11277000
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
16696000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
20647000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
24207000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41611000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54766000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-202847000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-50150000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
124528000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
258258000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
51276000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
40345000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
100029000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
79736000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
104164000
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
111807000
us-gaap Costs And Expenses
CostsAndExpenses
245204000
us-gaap Costs And Expenses
CostsAndExpenses
362201000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-44013000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-24164000
us-gaap Operating Income Loss
OperatingIncomeLoss
-124938000
us-gaap Operating Income Loss
OperatingIncomeLoss
-191524000
CY2022Q2 us-gaap Interest Expense
InterestExpense
6580000
CY2021Q2 us-gaap Interest Expense
InterestExpense
5747000
us-gaap Interest Expense
InterestExpense
15549000
us-gaap Interest Expense
InterestExpense
11395000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6222000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
443000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
475000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
72000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-50150000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29900000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-146234000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-29900000
us-gaap Net Income Loss
NetIncomeLoss
-146234000
us-gaap Net Income Loss
NetIncomeLoss
-202847000
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.89
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.73
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77554717
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75559697
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77405040
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74203858
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-50150000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-29900000
us-gaap Net Income Loss
NetIncomeLoss
-146234000
us-gaap Net Income Loss
NetIncomeLoss
-202847000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
40000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-50148000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-481000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-29860000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-146234000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-202844000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
97726000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6223000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3556000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-96084000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
127671000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-29900000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1423000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-313000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
544000
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2658000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4009000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13037000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
12563000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-50150000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8000
CY2022Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
642000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1655000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13935000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-22629000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
280974000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-172947000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4429000
CY2021Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1730000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16982000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-37000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
40903000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1985000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11512000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
40000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
156220000
us-gaap Profit Loss
ProfitLoss
-146234000
us-gaap Profit Loss
ProfitLoss
-202847000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1654000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1726000
us-gaap Share Based Compensation
ShareBasedCompensation
26729000
us-gaap Share Based Compensation
ShareBasedCompensation
28479000
us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-3210000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
4677000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2064000
chrs Upfront License Fee Payments Related To License And Collaboration Arrangements
UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements
35000000
chrs Upfront License Fee Payments Related To License And Collaboration Arrangements
UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements
136000000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6222000
chrs Other Noncash Adjustments
OtherNoncashAdjustments
1208000
chrs Other Noncash Adjustments
OtherNoncashAdjustments
1896000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-7327000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-15243000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
14203000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3860000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-6490000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2335000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-773000
chrs Increase Decrease In Accrued Rebates Fees And Reserve
IncreaseDecreaseInAccruedRebatesFeesAndReserve
-14480000
chrs Increase Decrease In Accrued Rebates Fees And Reserve
IncreaseDecreaseInAccruedRebatesFeesAndReserve
2229000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1134000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49291000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
109000000
us-gaap Repayments Of Debt
RepaymentsOfDebt
81750000
chrs Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
-5086000
chrs Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
-7428000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-8586000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
26461000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-104082000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1179000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1495000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
560000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
140330000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
15000000
chrs Upfront And Milestone Based License Fee Payments Investing Activities
UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities
35000000
chrs Upfront And Milestone Based License Fee Payments Investing Activities
UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities
136000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-36495000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-261890000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
191190000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
40903000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
552000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8446000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1655000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1985000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3300000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1730000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-141711000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-211420000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
417635000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
541598000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
275924000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
330178000
CY2022Q2 chrs Product Pipeline Number Of Drug Candidates
ProductPipelineNumberOfDrugCandidates
4
chrs Number Of Products
NumberOfProducts
2
chrs Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration
PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
350580000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
440000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
440000
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
60200000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
417635000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
541598000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
120300000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
275484000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Estimates are assessed </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">each period and updated to reflect current information. Accounting estimates and judgements are inherently uncertain and therefore actual results could differ from these estimates.</p>
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
417195000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
541158000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
329738000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
440000
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
440000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
275924000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
330178000
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
87600000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
170700000
CY2021Q4 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
109723000
chrs Reserve For Sales Discounts And Allowances Constitute Variable Consideration
ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
297606000
chrs Provision Related To Sales Made In Prior Period
ProvisionRelatedToSalesMadeInPriorPeriod
-5868000
chrs Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration
PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
305348000
CY2022Q2 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
96113000
CY2020Q4 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
123398000
chrs Reserve For Sales Discounts And Allowances Constitute Variable Consideration
ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
348974000
chrs Provision Related To Sales Made In Prior Period
ProvisionRelatedToSalesMadeInPriorPeriod
-7558000
CY2021Q2 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
114234000
CY2022Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2022Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
7685000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4870000
CY2022Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
69593000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
65117000
CY2022Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
30420000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
23265000
CY2022Q2 us-gaap Inventory Gross
InventoryGross
107698000
CY2021Q4 us-gaap Inventory Gross
InventoryGross
93252000
CY2022Q2 us-gaap Inventory Net
InventoryNet
31744000
CY2021Q4 us-gaap Inventory Net
InventoryNet
37642000
CY2022Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
75954000
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
55610000
CY2022Q2 chrs Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
107698000
CY2021Q4 chrs Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
93252000
CY2022Q2 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
7200000
CY2022Q2 chrs Prepayments Made To Cmo For Manufacturing Services
PrepaymentsMadeToCmoForManufacturingServices
3500000
CY2022Q2 chrs Prepayments Made To Cmo For Other Research And Development Pipeline Program
PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram
3700000
CY2021Q4 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
13700000
CY2021Q4 chrs Prepayments Made To Cmo For Manufacturing Services
PrepaymentsMadeToCmoForManufacturingServices
8300000
CY2021Q4 chrs Prepayments Made To Cmo For Other Research And Development Pipeline Program
PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram
5400000
CY2021Q1 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-3200000
CY2021Q2 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
0
CY2022Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
27933000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
24662000
CY2022Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
18380000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
16849000
CY2022Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
9553000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
7813000
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1700000
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1700000
CY2022Q2 chrs Accrued Clinical And Manufacturing Liabilities Current
AccruedClinicalAndManufacturingLiabilitiesCurrent
14781000
CY2021Q4 chrs Accrued Clinical And Manufacturing Liabilities Current
AccruedClinicalAndManufacturingLiabilitiesCurrent
30541000
CY2022Q2 chrs Accrued Co Development Costs For Toripalimab Current
AccruedCoDevelopmentCostsForToripalimabCurrent
12025000
CY2021Q4 chrs Accrued Co Development Costs For Toripalimab Current
AccruedCoDevelopmentCostsForToripalimabCurrent
1926000
CY2022Q2 chrs Lease Liabilities Operating And Financing
LeaseLiabilitiesOperatingAndFinancing
3988000
CY2021Q4 chrs Lease Liabilities Operating And Financing
LeaseLiabilitiesOperatingAndFinancing
3492000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
10999000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
12168000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
41793000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
48127000
CY2022Q1 chrs Collaboration Agreement Option Exercise Fee Per Program
CollaborationAgreementOptionExerciseFeePerProgram
35000000.0
CY2020Q2 us-gaap Share Price
SharePrice
14.815
CY2022Q2 us-gaap Share Price
SharePrice
7.24
CY2022Q2 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
25539000
CY2022Q2 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
16327000
CY2022Q2 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
911000
CY2022Q2 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
911000
CY2022Q2 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
208000
CY2022Q2 us-gaap Purchase Obligation
PurchaseObligation
43896000
CY2022Q2 us-gaap Product Liability Contingency Loss Exposure Not Accrued Best Estimate
ProductLiabilityContingencyLossExposureNotAccruedBestEstimate
14000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37309256
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
36557270
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37335701
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38700741

Files In Submission

Name View Source Status
0001558370-22-012251-index-headers.html Edgar Link pending
0001558370-22-012251-index.html Edgar Link pending
0001558370-22-012251.txt Edgar Link pending
0001558370-22-012251-xbrl.zip Edgar Link pending
chrs-20220630.xsd Edgar Link pending
chrs-20220630x10q.htm Edgar Link pending
chrs-20220630x10q_htm.xml Edgar Link completed
chrs-20220630xex10d1.htm Edgar Link pending
chrs-20220630xex31d1.htm Edgar Link pending
chrs-20220630xex31d2.htm Edgar Link pending
chrs-20220630xex32d1.htm Edgar Link pending
chrs-20220630_cal.xml Edgar Link unprocessable
chrs-20220630_def.xml Edgar Link unprocessable
chrs-20220630_lab.xml Edgar Link unprocessable
chrs-20220630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending